Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability
Year: 2018
Type: article
Abstract: Background: Androgen deprivation therapy (ADT) and surveillance are standard options for patients (pts) with biochemically recurrent (non-metastatic, castration sensitive) prostate cancer (BCRpc) after localized therapy. Enzalutamide (enz) extends survival in advanced prostate cancer and is being tested in earlier stages of disease.
Source: Annals of Oncology
Authors: M. Al Harthy, H. Singh, F. Karzai, P. Arlen, M. Theoret, J. Marte, M. Bilusic, A. Couvillon, H. Owens, A. Hankin, L. Cordes, I. Rosner, J. Strauss, W.D. Figg, J. Schlom, W. Dahut, J. Gulley, R. Madan
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898112260